BioLineRx Ltd. (BLRX)

0.86
0.01 1.16
NASDAQ : Health Technology
Prev Close 0.85
Open 0.86
Day Low/High 0.83 / 0.86
52 Wk Low/High 0.80 / 1.34
Volume 168.39K
Avg Volume 370.70K
Exchange NASDAQ
Shares Outstanding 105.44M
Market Cap 91.30M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioLineRx To Report Annual 2017 Results On March 6, 2018

BioLineRx To Report Annual 2017 Results On March 6, 2018

Management to hold a conference call at 10:00 a.m. EST

BioLineRx Reports Data At ASCO-SITC Conference Showing Complete Tumor Regression By AGI-134 In Pre-Clinical Studies

BioLineRx Reports Data At ASCO-SITC Conference Showing Complete Tumor Regression By AGI-134 In Pre-Clinical Studies

- AGI-134 on track to commence Phase 1/2a clinical study in H1 2018 -

BioLineRx Announces Partial Monotherapy Results From Phase 2a COMBAT Study In Pancreatic Cancer

BioLineRx Announces Partial Monotherapy Results From Phase 2a COMBAT Study In Pancreatic Cancer

- BL-8040 monotherapy resulted in increased infiltration of T cells into tumor -

BioLineRx Announces Initiation Of Phase 3 GENESIS Trial In Stem-Cell Mobilization For Autologous Transplantation In Multiple Myeloma Patients

BioLineRx Announces Initiation Of Phase 3 GENESIS Trial In Stem-Cell Mobilization For Autologous Transplantation In Multiple Myeloma Patients

Study will assess mobilization of hematopoietic stem cells by BL-8040 compared to placebo, on top of G-CSF, for autologous transplantation in multiple myeloma patients

BioLineRx Reports Overall Survival Results From Long-term Follow-up Of Phase 2a Trial In R/r AML

BioLineRx Reports Overall Survival Results From Long-term Follow-up Of Phase 2a Trial In R/r AML

BL-8040 in combination with high-dose Ara-C significantly improved overall survival compared to historical data

BioLineRx Announces Partial Results Of BL-8040 COMBAT Study Accepted For Presentation At ASCO 2018 Gastrointestinal Cancers Symposium

BioLineRx Announces Partial Results Of BL-8040 COMBAT Study Accepted For Presentation At ASCO 2018 Gastrointestinal Cancers Symposium

Enrollment to COMBAT study has been completed; full topline results expected in H2 2018 as planned

BioLineRx To Report Third Quarter 2017 Results On November 21, 2017

BioLineRx To Report Third Quarter 2017 Results On November 21, 2017

Management to hold a conference call at 10:00 a.m. EST

BioLineRx Announces Oral Presentation At ASH Of Data Supporting BL-8040 As Robust Mobilizer Of Hematopoietic Stem Cells (HSC) Associated With Long-Term Engraftment

BioLineRx Announces Oral Presentation At ASH Of Data Supporting BL-8040 As Robust Mobilizer Of Hematopoietic Stem Cells (HSC) Associated With Long-Term Engraftment

- Preclinical data demonstrate that BL-8040 mobilizes a significant number of these HSCs compared to G-CSF, thus potentially improving graft quality -

BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement

BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement

BioLineRx (BLRX) signed a licensing agreement with two Israeli companies to allow the development of a drug that treats liver failure conditions.

7 Stocks Under $10 to Trade for Big Profits

7 Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

7 Stocks Under $10 Making Big Moves

7 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BioLineRx Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Stem Cell Mobilization Treatment

BioLineRx Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Stem Cell Mobilization Treatment

BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory submissions...

BioLineRx Establishes Oncology Scientific Advisory Board

BioLineRx Establishes Oncology Scientific Advisory Board

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported the establishment of a Scientific...

BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015

BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it will host an investor breakfast...

BioLineRx To Present At The LD Micro Main Event

BioLineRx To Present At The LD Micro Main Event

BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer,...

BioLineRx Reports Third Quarter 2015 Financial Results

BioLineRx Reports Third Quarter 2015 Financial Results

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the third...

BioLineRx To Report Third Quarter 2015 Results On November 16, 2015

BioLineRx To Report Third Quarter 2015 Results On November 16, 2015

BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited...

BioLineRx Announces Positive Clinical Results From First Part Of Phase 2 Trial In R/r AML

BioLineRx Announces Positive Clinical Results From First Part Of Phase 2 Trial In R/r AML

BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today positive results from the dose...

BioLineRx's Novel Treatment For Non-Surgical Removal Of Skin Lesions Submitted For CE Mark Registration

BioLineRx's Novel Treatment For Non-Surgical Removal Of Skin Lesions Submitted For CE Mark Registration

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its partner, Omega Pharma,...

BioLineRx To Present At The 17th Annual Rodman & Renshaw Global Investment Conference In New York

BioLineRx To Present At The 17th Annual Rodman & Renshaw Global Investment Conference In New York

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer,...

BioLineRx Reports Second Quarter 2015 Financial Results

BioLineRx Reports Second Quarter 2015 Financial Results

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the...

BioLineRx Announces Initiation Of Phase 2b Trial For Novel AML Consolidation Treatment

BioLineRx Announces Initiation Of Phase 2b Trial For Novel AML Consolidation Treatment

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the initiation of a Phase 2b...

BioLineRx To Report Second Quarter 2015 Results On August 20, 2015

BioLineRx To Report Second Quarter 2015 Results On August 20, 2015

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its...

BioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Results

BioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Results

BioLineRx (BLRX) shares are down by almost 20% after the company confirmed weak results from its placebo-controlled heart disease treatment tests.